BioNTech earnings drop but forecast for vaccine income grows

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported that third-quarter earnings are close to half what they were a year earlier

BERLIN — BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, reported that its earnings in the third quarter were close to half what they were a year earlier, but the German pharmaceutical company still raised its expectations for vaccine revenue after rolling out updated shots targeting omicron strains.

The company said Monday that it made net profit of 1.8 billion euros ($1.8 billion) off revenue of 3.5 billion euros ($3.5 billion) in the three months to September, a drop from profit of 3.2 billion euros and revenue of 6.1 billion euros in the same period a year ago.

BioNTech said “the course of the pandemic remains dynamic and led to fluctuations” in earnings. Profit and revenue were largely flat in the first nine months of the year.

“Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range,” said Jens Holstein, CFO of BioNTech. “We started shipments of our Omicron-adapted bivalent vaccines early in September, and we expect to carry on with our deliveries throughout the fourth quarter of 2022.”

Citing those updated vaccines, the company says it expects to make 16 billion to 17 billion euros in revenue from COVID-19 vaccines vs. the previous forecast of 13 billion to 17 billion euros.

The German company splits profits and costs to make and distribute the vaccines with New York-based Pfizer.

Pfizer said last week that its COVID-19 pill treatment Paxlovid helped it balance tumbling international sales for its coronavirus vaccine and top third-quarter expectations.

BioNTech said it’s sold about 300 million doses of the updated COVID-19 vaccines that target omicron strains as of mid-October.

The company says it and Pfizer have delivered a total of about 1.6 billion doses to low- and middle-income countries. Unlike Moderna, Pfizer and BioNTech have not yet agreed to a supply deal for their latest omicron-adapted shots with COVAX, the U.N.-backed program to ship vaccines to poor countries.

Source ABC

A tech blog author and superhero who writes about technology and its impact on society, business, and everyday life

Related Posts

China reports 2 new COVID deaths as some restrictions eased

HONG KONG — China on Sunday reported two additional deaths from COVID-19 as some cities move cautiously to ease anti-pandemic restrictions amid increasingly vocal public frustration over the measures. The…

Read more

NY state health commissioner resigning to return to Harvard

ALBANY, N.Y. — New York’s state health commissioner will resign Jan. 1 after 13 months in the job to return to Harvard University’s T.H. Chan School of Public Health. Mary…

Read more

Beijing, Shenzhen scrap COVID-19 tests for public transport

BEIJING — Chinese authorities on Saturday announced a further easing of COVID-19 curbs with major cities such as Shenzhen and Beijing no longer requiring negative tests to take public transport….

Read more

Indiana judge won’t block probe over 10-year-old’s abortion

INDIANAPOLIS — An Indiana judge on Friday rejected an attempt to block the state’s Republican attorney general from continuing his office’s investigation of an Indianapolis doctor who has spoken publicly…

Read more

Flu season worsens as 44 states report high activity

FILE – A flu vaccine is readied at the L.A. Care and Blue Shield of California Promise Health Plans’ Community Resource Center where they were offering members and the public…

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *